Esophageal Cancer Clinical Trial

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Summary

The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma

The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

View Full Description

Full Description

There will be 2 parts to the study: the cisplatin and 5-fluorouracil (5-FU) (FP) and paclitaxel and cisplatin (TP) Safety Run-in (Part 1) and the Main Study (Part 2). In Part 1 (FP and TP Safety Run-in), participants will be treated with pembrolizumab plus lenvatinib plus FP or TP. Dose-limiting toxicities, safety, and tolerability will be assessed.

In Part 2 (Main Study), participants (not including those participating in Part 1) will be treated with pembrolizumab plus lenvatinib plus chemotherapy or pembrolizumab plus chemotherapy. Efficacy, safety, and tolerability will be assessed.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Has a histologically or cytologically confirmed diagnosis of metastatic squamous cell carcinoma of the esophagus
Male participants are abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 7 days after the last dose of lenvatinib or 90 days after the last dose of chemotherapy, whichever comes last; 7 days after lenvatinib is stopped, if the participant is on pembrolizumab only and is greater than 90 days post chemotherapy, no male contraception is needed
Female participant is not pregnant or breastfeeding and is not a woman of childbearing potential (WOCBP) or is a WOCBP using a contraceptive method that is highly effective or is abstinent from heterosexual intercourse as their preferred and usual lifestyle during the intervention period and for at least 120 days after the last dose of pembrolizumab, 30 days after the last dose of lenvatinib, or 180 days after the last dose of chemotherapy, whichever occurs last, and agrees not to donate eggs during this period
Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP≤150/90 millimeters of mercury (mm Hg) with no change in antihypertensive medications within 1 week prior to randomization
Has adequate organ function

Exclusion Criteria:

Has had previous therapy for locally advanced unresectable or metastatic esophageal cancer
Has locally advanced esophageal carcinoma
Has metastatic adenocarcinoma of the esophagus
Has direct invasion into adjacent organs such as the aorta or trachea
Has radiographic evidence of encasement of a major blood vessel, or of intratumoral cavitation
Has perforation risks or significant gastrointestinal (GI) bleeding
Has had clinically significant hemoptysis within 3 weeks prior to the first dose of study drug or tumor bleeding within 2 weeks prior to the first dose of study intervention
Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention
Has GI obstruction, poor oral intake, difficulty in taking oral medication, or existing esophageal stent
Has had major surgery, open biopsy, or significant traumatic injury within 3 weeks prior to first dose of study interventions
Has received prior radiotherapy within 2 weeks of start of study intervention or have had a history of radiation pneumonitis
Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention; administration of killed vaccines is allowed
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to the first dose of study intervention, or has a history of organ transplant, including allogeneic stem cell transplant
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Has an active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy is not considered a form of systemic treatment and is allowed
Has a history of non-infectious pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease
Has poorly controlled diarrhea
Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
Has peripheral neuropathy ≥Grade 2
Has a known history of human immunodeficiency virus (HIV) infection
Has a known history of Hepatitis B or know active Hepatitis C virus infection
Has a weight loss of >20% within the last 3 months

Study is for people with:

Esophageal Cancer

Phase:

Phase 3

Estimated Enrollment:

862

Study ID:

NCT04949256

Recruitment Status:

Recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 133 Locations for this study

See Locations Near You

City of Hope ( Site 0102)
Duarte California, 91010, United States More Info
Study Coordinator
Contact
626-256-4673
James Graham Brown Cancer Center ( Site 0117)
Louisville Kentucky, 40202, United States More Info
Study Coordinator
Contact
502-314-0369
Norton Cancer Institute ( Site 0116)
Louisville Kentucky, 40217, United States More Info
Study Coordinator
Contact
502-636-7845
Johns Hopkins Bayview Medical Center ( Site 0152)
Baltimore Maryland, 21224, United States More Info
Study Coordinator
Contact
410-550-5358
UMASS Memorial Medical Center ( Site 0120)
Worcester Massachusetts, 01655, United States More Info
Study Coordinator
Contact
508-856-3216
Hematology-Oncology Associates of CNY ( Site 0173)
East Syracuse New York, 13057, United States More Info
Study Coordinator
Contact
315-472-7504
Memorial Sloan Kettering Cancer Center ( Site 0132)
New York New York, 10065, United States More Info
Study Coordinator
Contact
646-888-4588
Weill Cornell Medical College ( Site 0133)
New York New York, 10065, United States More Info
Study Coordinator
Contact
646-962-6200
Seattle Cancer Care Alliance ( Site 0145)
Seattle Washington, 98109, United States More Info
Study Coordinator
Contact
810-423-3800
Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0203)
Berazategui Buenos Aires, B1884, Argentina More Info
Study Coordinator
Contact
+541142262013
IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0202)
Caba Buenos Aires, C1012, Argentina More Info
Study Coordinator
Contact
+54115031-9779
Instituto de Investigaciones Clinicas Mar del Plata ( Site 0205)
Mar del Plata Buenos Aires, B7600, Argentina More Info
Study Coordinator
Contact
+5492235937663
Sanatorio Parque ( Site 0206)
Rosario Santa Fe, S2000, Argentina More Info
Study Coordinator
Contact
+543414200250
Fundacion Favaloro ( Site 0201)
Buenos Aires , C1093, Argentina More Info
Study Coordinator
Contact
549 1150523121
Instituto San Marcos ( Site 0213)
San Juan , J5400, Argentina More Info
Study Coordinator
Contact
+549-264-507141
James Lind Centro de Investigación del Cáncer ( Site 0412)
Temuco Araucania, 48008, Chile More Info
Study Coordinator
Contact
+56994443272
Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0401)
Temuco Araucania, 48102, Chile More Info
Study Coordinator
Contact
+56452657374
Fundacion Arturo Lopez Perez FALP ( Site 0403)
Santiago Region M. De Santiago, 75008, Chile More Info
Study Coordinator
Contact
569981369487
Oncovida ( Site 0413)
Santiago Region M. De Santiago, 75100, Chile More Info
Study Coordinator
Contact
+56225992980
Clínica San Carlos de Apoquindo Red Salud UC Christus ( Site 0407)
Santiago Region M. De Santiago, 75500, Chile More Info
Study Coordinator
Contact
56227548924
Bradford Hill Centro de Investigaciones Clinicas ( Site 0404)
Santiago Region M. De Santiago, 84203, Chile More Info
Study Coordinator
Contact
+56229490970
Anhui Cancer Hospital ( Site 8058)
Hefei Anhui, 23003, China More Info
Study Coordinator
Contact
0551-65327666
The Second Affiliated Hospital of Anhui Medical University ( Site 8026)
Hefei Anhui, 23003, China More Info
Study Coordinator
Contact
0551-63869420
Beijing Cancer Hospital ( Site 8001)
Beijing Beijing, 10014, China More Info
Study Coordinator
Contact
+8613911219511
Fujian Provincial Cancer Hospital ( Site 8029)
Fuzhou Fujian, 35001, China More Info
Study Coordinator
Contact
+8613809500871
The First Affiliated Hospital of Xiamen University ( Site 8003)
Xiamen Fujian, 36100, China More Info
Study Coordinator
Contact
+8613860458889
Zhongshan Hospital Affiliated to Xiamen University ( Site 8055)
Xiamen Fujian, 36100, China More Info
Study Coordinator
Contact
+8615880277305
The First Affiliated Hospital.Sun Yat-sen University ( Site 8047)
Guangzhou Guangdong, 51008, China More Info
Study Coordinator
Contact
020-87755766
Southern Medical University Nanfang Hospital ( Site 8031)
Guangzhou Guangdong, 51051, China More Info
Study Coordinator
Contact
18820408460
The Third Xiangya Hospital of Central South University ( Site 8046)
Changsha Hainan, 41001, China More Info
Study Coordinator
Contact
+861378731809
The First Affiliated Hospital of Hainan Medical University ( Site 8042)
Haikou Hainan, 57010, China More Info
Study Coordinator
Contact
+86 898 66737967
Affiliated Hospital of Chengde Medical Univeristy ( Site 8053)
Chengde Hebei, 06705, China More Info
Study Coordinator
Contact
+8615633142750
Harbin Medical University Cancer Hospital ( Site 8009)
Harbin Heilongjiang, , China More Info
Study Coordinator
Contact
+8613845120210
Anyang Cancer Hospital ( Site 8006)
Anyang Henan, 45500, China More Info
Study Coordinator
Contact
13503723589
The First Affiliated Hospital of Henan University of Science &Technology-Tumor ( Site 8036)
Luoyang Henan, 47100, China More Info
Study Coordinator
Contact
0379-64820110
The First Affiliated Hospital of Xinxiang Medical University ( Site 8018)
Xinxiang Henan, 45310, China More Info
Study Coordinator
Contact
13663030446
Tongji Medical College Huazhong Uinversity Of Science and Technology ( Site 8025)
Wuhan Hubei, 43003, China More Info
Study Coordinator
Contact
+862783662688
Hubei Cancer Hospital ( Site 8014)
Wuhan Hubei, 43007, China More Info
Study Coordinator
Contact
027-87670003
Affiliated hospital of Jiangnan university ( Site 8049)
Wuxi Jiangsu, 21412, China More Info
Study Coordinator
Contact
+8613506198192
The Affiliated Hospital of Xuzhou Medical University ( Site 8015)
Xuzhou Jiangsu, 22100, China More Info
Study Coordinator
Contact
0516-85609999
Jilin Cancer Hospital ( Site 8016)
Changchun Jilin, 13001, China More Info
Study Coordinator
Contact
13943012851
Jinan Central Hospital ( Site 8052)
Jinan Shandong, 25001, China More Info
Study Coordinator
Contact
+86053155863107
Affiliated Hospital of Jining Medical University ( Site 8017)
Jining Shandong, 27200, China More Info
Study Coordinator
Contact
+8605372903595
Linyi Cancer Hospital- Medical Oncology Department ( Site 8051)
Linyi Shandong, 27600, China More Info
Study Coordinator
Contact
+8605398122693
Shanxi Provincial Cancer Hospital ( Site 8019)
Taiyuan Shanxi, 03001, China More Info
Study Coordinator
Contact
13834646436
West China Hospital of Sichuan University ( Site 8048)
Chengdu Sichuan, 61004, China More Info
Study Coordinator
Contact
18980606593
Tianjin Medical University Cancer Institute & Hospital ( Site 8035)
Tianjin Tianjin, 30006, China More Info
Study Coordinator
Contact
+8618920193527
Cancer Hospital Affiliated to Xinjiang Medical University ( Site 8041)
Urumqi Xinjiang, 83000, China More Info
Study Coordinator
Contact
18160627936
Sir Run Run Shaw Hospital ( Site 8021)
Hangzhou Zhejiang, 31001, China More Info
Study Coordinator
Contact
0571-86090073
CIMCA Centro de Investigacion y Manejo del Cancer ( Site 0902)
San Jose , 10103, Costa Rica More Info
Study Coordinator
Contact
+50683893636
Onco Tech S A ( Site 0901)
San Jose , 10103, Costa Rica More Info
Study Coordinator
Contact
+50688886626
Rigshospitalet ( Site 2102)
Copenhagen Hovedstaden, 2100, Denmark More Info
Study Coordinator
Contact
35455072
Odense University Hospital ( Site 2101)
Odense Syddanmark, 5000, Denmark More Info
Study Coordinator
Contact
+4566113333
Institut De Cancerologie De Lorraine ( Site 1010)
Vandoeuvre les Nancy Ain, 54519, France More Info
Study Coordinator
Contact
33 3 83 59 85 64
Centre Hospitalier Régional Universitaire de Brest - Hôpital-Institut de cancérologie et hématologi
Brest Bretagne, 29200, France More Info
Study Coordinator
Contact
33298223428
Centre Georges Francois Leclerc ( Site 1008)
Dijon Cote-d Or, 21000, France More Info
Study Coordinator
Contact
03 45 34 80 68
CHU Bordeaux Haut-Leveque ( Site 1012)
Pessac Gironde, 33604, France More Info
Study Coordinator
Contact
+33556795679
Institut du Cancer de Montpellier ( Site 1002)
Montpellier Herault, 34298, France More Info
Study Coordinator
Contact
+33467613136
CHRU de Tours - Hopital Bretonneau ( Site 1018)
Tours Indre-et-Loire, 37044, France More Info
Study Coordinator
Contact
+33147475900
Institut De Cancerologie De L Ouest ( Site 1003)
Saint Herblain Loire-Atlantique, 44805, France More Info
Study Coordinator
Contact
33240679900
Hôpital Claude Huriez ( Site 1030)
Lille Nord, 59000, France More Info
Study Coordinator
Contact
+33320445461
Hopital Henri Mondor ( Site 1007)
Creteil Val-de-Marne, 94010, France More Info
Study Coordinator
Contact
33149812567
Hopital Saint Louis ( Site 1029)
Paris , 75010, France More Info
Study Coordinator
Contact
33142499597
Centro Regional de Sub Especialidades Medicas SA ( Site 0604)
Guatemala Quetzaltenango, 09001, Guatemala More Info
Study Coordinator
Contact
+50259450559
Oncomedica ( Site 0602)
Guatemala , 01010, Guatemala More Info
Study Coordinator
Contact
+50222781269
Soluciones Gastrointestinales S.A. ( Site 0607)
Guatemala , 01010, Guatemala More Info
Study Coordinator
Contact
+50245711895
Medi-K Cayala ( Site 0601)
Guatemala , 01016, Guatemala More Info
Study Coordinator
Contact
+50255505555
Queen Mary Hospital ( Site 4001)
Hong Kong , , Hong Kong More Info
Study Coordinator
Contact
+85222554352
Queen Elizabeth Hospital. ( Site 4004)
Kowloon , , Hong Kong More Info
Study Coordinator
Contact
+85235062851
Pecsi Tudomanyegyetem AOK ( Site 1204)
Pecs Baranya, 7624, Hungary More Info
Study Coordinator
Contact
3672536000
Petz Aladar Egyetemi Oktato Korhaz ( Site 1210)
Gyor Gyor-Moson-Sopron, 9024, Hungary More Info
Study Coordinator
Contact
36964182446104
Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1203)
Szolnok Jasz-Nagykun-Szolnok, 5000, Hungary More Info
Study Coordinator
Contact
36209323256
Orszagos Onkologiai Intezet ( Site 1207)
Budapest , 1122, Hungary More Info
Study Coordinator
Contact
36122486003209
A.O.U. Santa Maria della Misericordia di Udine ( Site 1302)
Udine Friuli-Venezia Giulia, 33100, Italy More Info
Study Coordinator
Contact
+390432559304
IRCCS Ospedale San Raffaele di Milano ( Site 1304)
Milano Lombardia, 20132, Italy More Info
Study Coordinator
Contact
+390226437624
Humanitas Research Hospital ( Site 1309)
Rozzano Lombardia, 20089, Italy More Info
Study Coordinator
Contact
+390282244080
Azienda Ospedaliero Universitaria Careggi ( Site 1301)
Firenze , 50134, Italy More Info
Study Coordinator
Contact
+390552751818
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1306)
Milano , 20133, Italy More Info
Study Coordinator
Contact
390223903835
A.O. Universitaria di Modena ( Site 1307)
Modena , 41124, Italy More Info
Study Coordinator
Contact
+390594224383
A.O.U. Universita degli Studi della Campania-Luigi Vanvitelli ( Site 1305)
Napoli , 80131, Italy More Info
Study Coordinator
Contact
+390815666713
Universita Cattolica del Sacro Cuore - Policlinico Gemelli ( Site 1310)
Roma , 00168, Italy More Info
Study Coordinator
Contact
+390630154953
National Cancer Center Hospital East ( Site 9002)
Kashiwa Chiba, 277-8, Japan More Info
Study Coordinator
Contact
+81-4-7133-1111
National Hospital Organization Shikoku Cancer Center ( Site 9019)
Matsuyama Ehime, 791-0, Japan More Info
Study Coordinator
Contact
+81-89-999-1111
Hyogo Cancer Center ( Site 9014)
Akashi Hyogo, 673-8, Japan More Info
Study Coordinator
Contact
+81-78-929-1151
Ibaraki Prefectural Central Hospital ( Site 9007)
Kasama Ibaraki, 309-1, Japan More Info
Study Coordinator
Contact
+81-296-77-1121
Kagawa University Hospital ( Site 9015)
Kita Kagawa, 761-0, Japan More Info
Study Coordinator
Contact
+81-87-898-5111
Kanagawa Cancer Center ( Site 9004)
Yokohama Kanagawa, 241-8, Japan More Info
Study Coordinator
Contact
+81-45-520-2222
Tohoku University Hospital ( Site 9013)
Sendai-shi Miyagi, 980-8, Japan More Info
Study Coordinator
Contact
+81-22-717-7000
Kindai University Hospital- Osakasayama Campus ( Site 9017)
Osaka-sayama Osaka, 589-8, Japan More Info
Study Coordinator
Contact
+81-72-366-0221
Osaka Medical and Pharmaceutical University Hospital ( Site 9008)
Takatsuki Osaka, 569-8, Japan More Info
Study Coordinator
Contact
+81-72-683-1221
Saitama Cancer Center ( Site 9003)
Kitaadachi-gun Saitama, 362-0, Japan More Info
Study Coordinator
Contact
+81-48-722-1111
Shizuoka Cancer Center ( Site 9016)
Nagaizumi Shizuoka, 411-8, Japan More Info
Study Coordinator
Contact
+81-55-989-5222
National Hospital Organization Kyushu Cancer Center ( Site 9010)
Fukuoka , 811-1, Japan More Info
Study Coordinator
Contact
+81-92-541-3231
Kyoto University Hospital ( Site 9011)
Kyoto , 606-8, Japan More Info
Study Coordinator
Contact
+81-75-751-3111
Osaka International Cancer Institute ( Site 9009)
Osaka , 541-8, Japan More Info
Study Coordinator
Contact
+81-6-6945-1181
Osaka General Medical Center ( Site 9018)
Osaka , 558-8, Japan More Info
Study Coordinator
Contact
+81-6-6692-1201
National Cancer Center Hospital ( Site 9001)
Tokyo , 104-0, Japan More Info
Study Coordinator
Contact
+81-3-3542-2511
The Cancer Institute Hospital of JFCR ( Site 9005)
Tokyo , 135-8, Japan More Info
Study Coordinator
Contact
+81-3-3520-0111
Keio university hospital ( Site 9020)
Tokyo , 160-8, Japan More Info
Study Coordinator
Contact
+81-3-3353-1211
Seoul National University Bundang Hospital ( Site 5006)
Seongnam-si Kyonggi-do, 13605, Korea, Republic of More Info
Study Coordinator
Contact
+82317877003
Asan Medical Center ( Site 5002)
Songpagu Seoul, 05505, Korea, Republic of More Info
Study Coordinator
Contact
+82230103217
Severance Hospital ( Site 5003)
Seoul , 03722, Korea, Republic of More Info
Study Coordinator
Contact
+82222284190
Samsung Medical Center ( Site 5005)
Seoul , 06351, Korea, Republic of More Info
Study Coordinator
Contact
82-2-3410-6518
Korea University Guro Hospital ( Site 5001)
Seoul , 08308, Korea, Republic of More Info
Study Coordinator
Contact
+82226263060
Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1507)
Ufa Baskortostan, Respublika, 45005, Russian Federation
FSBI National Medical Oncology Research Center n.a. N.N. Blokhina ( Site 1510)
Moscow Moskva, 11547, Russian Federation
SBHI Leningrad Regional Oncology Dispensary ( Site 1502)
Saint Petersburg Sankt-Peterburg, 18866, Russian Federation
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1503)
Saint Petersburg Sankt-Peterburg, 19775, Russian Federation
Academician I.P. Pavlov First St. Petersburg State Medical University ( Site 1519)
Saint-Petersburg Sankt-Peterburg, 19702, Russian Federation
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1509)
Kazan Tatarstan, Respublika, 42002, Russian Federation
SAIH of Tyumen reg "Multifield clinical medical center "Medical city" ( Site 1520)
Tyumen Tyumenskaya Oblast, 62504, Russian Federation
Hospital Universitario General de Asturias ( Site 1601)
Oviedo Asturias, 33011, Spain More Info
Study Coordinator
Contact
+34985106100
Hospital Universitario Marques de Valdecilla ( Site 1602)
Santander Cantabria, 39008, Spain More Info
Study Coordinator
Contact
+34942202525
Hospital General Universitari Vall d Hebron ( Site 1607)
Barcelona , 08035, Spain More Info
Study Coordinator
Contact
34932746085
Hospital General Universitario Gregorio Maranon ( Site 1604)
Madrid , 28007, Spain More Info
Study Coordinator
Contact
+34914269393
Hospital Virgen del Rocio ( Site 1606)
Sevilla , 41013, Spain More Info
Study Coordinator
Contact
+34955012000
Chang Gung Med Foundation. Kaohsiung Branch ( Site 6005)
Kaohsiung , 83301, Taiwan More Info
Study Coordinator
Contact
+88677317123
China Medical University Hospital ( Site 6003)
Taichung , 40447, Taiwan More Info
Study Coordinator
Contact
+886422052121
National Cheng Kung University Hospital ( Site 6004)
Tainan , 704, Taiwan More Info
Study Coordinator
Contact
+886623535354620
National Taiwan University Hospital ( Site 6001)
Taipei , 10002, Taiwan More Info
Study Coordinator
Contact
+8862231234567680
Taipei Veterans General Hospital ( Site 6006)
Taipei , 11217, Taiwan More Info
Study Coordinator
Contact
+8862287121212573
Medeniyet Universitesi Tip Fakultesi ( Site 1703)
Istambul Istanbul, 34732, Turkey More Info
Study Coordinator
Contact
00905063509061
Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1701)
Ankara , 06230, Turkey More Info
Study Coordinator
Contact
903123052910
Memorial Ankara Hastanesi ( Site 1702)
Ankara , 06520, Turkey More Info
Study Coordinator
Contact
+9003122536666/1209
Ataturk Universitesi Tip Fakultesi Hastanesi ( Site 1712)
Erzurum , 25240, Turkey More Info
Study Coordinator
Contact
905072864555
Istanbul Okmeydanı Egitim ve Arastirma Hastanesi ( Site 1711)
Istanbul , 34384, Turkey More Info
Study Coordinator
Contact
905058843439
Chernihiv Medical Center of Modern Oncology ( Site 1811)
Chernihiv Chernihivska Oblast, 14029, Ukraine
MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council ( Site 1804)
Kryviy Rih Dnipropetrovska Oblast, 50048, Ukraine More Info
Study Coordinator
Contact
380675393937
Kharkiv Regional Clinical Oncology Center ( Site 1812)
Kharkiv Kharkivska Oblast, 61000, Ukraine More Info
Study Coordinator
Contact
+380660827918
Institute of General and Emergency Surgery n.a Zaitsev NAMS of Ukraine ( Site 1813)
Kharkiv Kharkivska Oblast, 61103, Ukraine More Info
Study Coordinator
Contact
+380503233704
Communal nonprofit enterprise "Kherson Regional Oncology Dispensary" of Kherson Regional Council (
Antonivka Village Khersonska Oblast, 73000, Ukraine
National Cancer Institute of the MoH of Ukraine ( Site 1806)
Kyiv Kyivska Oblast, 03022, Ukraine
Podillya Regional Center of Oncology ( Site 1809)
Vinnytsia Vinnytska Oblast, 21029, Ukraine
Volyn Regional Oncological Dispensary ( Site 1816)
Lutsk Volynska Oblast, 43018, Ukraine
Cambridge University Hospitals NHSFT ( Site 1908)
Cambridge Cambridgeshire, CB2 0, United Kingdom More Info
Study Coordinator
Contact
+44(0)1223 216083
Ninewells Hospital and Medical School ( Site 1907)
Dundee Dundee City, DD1 9, United Kingdom More Info
Study Coordinator
Contact
01382 660111 x 5363
Nottingham University Hospital NHS Trust ( Site 1910)
Nottingham England, NG5 1, United Kingdom More Info
Study Coordinator
Contact
+44 (0)115 969 1169
University College London Hospitals NHS Foundation Trust ( Site 1901)
London London, City Of, NW1 2, United Kingdom More Info
Study Coordinator
Contact
+442034577126
Royal Marsden NHS Foundation Trust ( Site 1905)
London London, City Of, SW3 6, United Kingdom More Info
Study Coordinator
Contact
+44(0)208 642 6011
Royal Marsden NHS Trust. ( Site 1906)
Sutton London, City Of, SM25P, United Kingdom More Info
Study Coordinator
Contact
+44(0)208 642 6011
Western General Hospital ( Site 1912)
Edinburgh Midlothian, EH4 2, United Kingdom More Info
Study Coordinator
Contact
0131 537 1000
The Christie NHS Foundation Trust ( Site 1909)
Manchester , M20 4, United Kingdom More Info
Study Coordinator
Contact
+441614468342

How clear is this clinincal trial information?

Study is for people with:

Esophageal Cancer

Phase:

Phase 3

Estimated Enrollment:

862

Study ID:

NCT04949256

Recruitment Status:

Recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.